ArticleBMC nephrology2025
Incidence and risk factors of post-transplant diabetes mellitus among kidney transplant recipients: a retrospective study from a tertiary center in Saudi Arabia.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-transplant diabetes mellitus (PTDM) is a common metabolic complication following kidney transplantation, adversely affecting graft and patient outcomes. This study aims to identify the prevalence, risk factors, and clinical implications of PTDM among kidney transplant recipients at Alhada Armed Forces Hospital, Taif, Saudi Arabia.
methodsWe conducted a retrospective cohort study including adult kidney transplant recipients from January 1984 to December 2023, excluding patients with pre-existing diabetes. Data were extracted from electronic medical records, encompassing demographics, clinical characteristics, transplantation details, and laboratory parameters. PTDM was diagnosed based on the American Diabetes Association criteria. Statistical analyses included t-tests, multivariate logistic regression, chi-square tests, Mann-Whitney U test, and Fisher’s exact tests. Receiver operating characteristic (ROC) curve analysis determined optimal cutoff values for predictive variables.
resultsOf 228 kidney transplant recipients (64% males, mean age 47.2 ± 14.6 years), 54 (23.7%) developed PTDM. PTDM patients were significantly older (53.1 ± 12.9 vs. 45.4 ± 14.6 years, p < 0.001) and had higher BMI (27.0 ± 4.7 vs. 25.2 ± 5.4 kg/m², p = 0.023). Hypertension was a more frequent cause of ESRD in the PTDM group (24.1% vs. 6.3%, p = 0.006). Tacrolimus levels ≥ 7 ng/mL were associated with higher PTDM incidence (70% vs. 52%, p = 0.032). Hypomagnesemia and uACR were also higher in PTDM patients compared to non-PTDM. Multivariate logistic regression identified age, hypomagnesaemia, uACR ≥ 9, and tacrolimus levels > 7 as independent PTDM predictors (p < 0.05).
conclusionsPTDM affects a substantial proportion of kidney transplant recipients, with older age, hypomagnesemia, increased uACR, and elevated tacrolimus levels emerging as key risk factors. Close monitoring and individualized immunosuppressive strategies may mitigate PTDM risk and improve post-transplant outcomes.
trial registrationNot applicable. The study is not a clinical trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.